Remove Big Data Remove Engineer Remove Genome Remove Protein
article thumbnail

Big data – charting a new path to drug discovery and development

Drug Discovery World

Drug discovery and development timelines can span 10-15 years or more from initial discovery to market approval and typically require the analysis of massive amounts of data. This knowledge enabled cell line engineering campaigns that boosted yield and stability across various production bottlenecks.

article thumbnail

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. Verily’s Immune Profiler can, Kim asserted, “generate more than 8 million immune measures across 24 immune cell subsets”.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How digital innovation is helping therapeutics to get to market faster

Drug Discovery World

Sanofi has stated that it intends to become the first pharma company “powered by AI at scale”, and as part of this ambition, agreed a collaboration with BioMap to co-develop advanced AI models and protein Large Language Models that that it hopes will enable biologics design and multiparametric optimisation 2.

article thumbnail

The DDW Podcast: 2023 in review

Drug Discovery World

In September, Shelley Ackerman, a biological engineer turned immunologist with a passion for drug discovery and development, spoke about the work being carried out at Bolt BioTherapeutics, where she is the Director & Program Team Lead. A deep dive into US drug discovery What lies in the future for genomics and big data?

article thumbnail

How big data analytics can make personalised care a reality

Drug Discovery World

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care. He holds an MS degree in Statistics and a BS-equivalent in Bioengineering.

article thumbnail

The challenges and trends of cell & gene therapies 

Drug Discovery World

The mysteries of cancer are starting to yield to the range of advanced therapies available and cell therapies – especially engineered cell therapies – are at the leading edge of that progress.” – Carlo Russo, CEO of Genenta.? . “In Research into genomic medicines is only at its infancy. Chris Nowers, CEO, ONK Therapeutics. . “

article thumbnail

Can artificial intelligence help craft new medicines?

Drug Discovery World

The drug target for Penicillin is a protein that helps bacteria to synthesise its cell wall. One of the first and most basic requirements for a protein to be characterised as a drug target is to show that inhibiting its function prevents the disease. Big data handling and machine learning made progress by leaps.